CIK 0000926617
- Non-accelerated filer
- Smaller reporting company
Aspira Women's Health Inc.
Sign in to watch- Ticker
- AWHL
- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330595156
- Phone
- +1 512-519-0400
- Business address
- 12117 BEE CAVES ROAD BUILDING THREE, SUITE 100, AUSTIN, TX, 78738
- Former names
- VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 30,932 shares at an average $1.70 ($52,530)
- 4 Open-market buy VP, Sales and Marketing bought 3,000 shares at an average $1.75 ($5,248)
- 4 Open-market buy Chief Accounting Officer bought 19,525 shares at an average $1.18 ($23,044)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy VP Sales and Marketing bought 957 shares at $1.98 ($1,895)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy VP Sales and Marketing bought 767 shares at $2.81 ($2,155)
- 4 Grant or award Director acquired 9,495 shares (grant or award)
- 4 Open-market buy VP of Corporate Strategy bought 2,000 shares at an average $3.01 ($6,016)
- 4 Open-market buy VP Sales and Marketing bought 717 shares at $2.81 ($2,015)
- 4 Open-market buy VP Sales and Marketing bought 1,000 shares at $2.75 ($2,750)
- 4 Open-market buy VP Sales and Marketing bought 500 shares at $4.16 ($2,080)
- 4 Open-market buy VP Sales and Marketing bought 489 shares at $4.04 ($1,976)
- 4 Open-market buy S.V.P & C.S.O bought 1,000 shares at $4.72 ($4,720)
- 4 Open-market sale Director sold 4,000 shares at $4.98 ($19,920)
Page 20 of 28 · 551 filings